Headlines about Supernus Pharmaceuticals (NASDAQ:SUPN) have been trending somewhat positive on Monday, Accern reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Supernus Pharmaceuticals earned a news impact score of 0.22 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 46.2490379937036 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s analysis:
- Supernus Pharmaceuticals (SUPN) Rating Increased to Buy at BidaskClub (americanbankingnews.com)
- Supernus Pharmaceuticals Inc (SUPN) Given Average Rating of “Buy” by Brokerages (americanbankingnews.com)
- Sell or Hold action? Supernus Pharmaceuticals, Inc. (SUPN) – Nasdaq Chronicle (nasdaqchronicle.com)
- Supernus Pharmaceuticals inks deal for new, expanded headquarters – Washington Business Journal (bizjournals.com)
- FY2018 Earnings Estimate for Supernus Pharmaceuticals Inc Issued By Cantor Fitzgerald (SUPN) (americanbankingnews.com)
A number of brokerages recently weighed in on SUPN. B. Riley restated a “buy” rating and set a $54.00 target price on shares of Supernus Pharmaceuticals in a report on Thursday, January 18th. Janney Montgomery Scott upgraded shares of Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 target price for the company in a report on Monday, December 4th. Berenberg Bank assumed coverage on shares of Supernus Pharmaceuticals in a research note on Thursday, February 1st. They issued a “buy” rating and a $66.00 price objective for the company. BidaskClub raised shares of Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 11th. Finally, ValuEngine lowered shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Two analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $51.36.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.02. Supernus Pharmaceuticals had a net margin of 18.95% and a return on equity of 28.07%. The firm had revenue of $80.40 million during the quarter, compared to analyst estimates of $78.74 million. The business’s quarterly revenue was up 41.5% compared to the same quarter last year. equities research analysts predict that Supernus Pharmaceuticals will post 1.87 earnings per share for the current year.
In other Supernus Pharmaceuticals news, VP Padmanabh P. Bhatt sold 20,000 shares of the stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $48.04, for a total value of $960,800.00. Following the completion of the sale, the vice president now owns 32,500 shares in the company, valued at approximately $1,561,300. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Victor Vaughn sold 15,000 shares of the stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $42.04, for a total transaction of $630,600.00. Following the completion of the sale, the vice president now owns 24,344 shares of the company’s stock, valued at approximately $1,023,421.76. The disclosure for this sale can be found here. Insiders sold a total of 165,750 shares of company stock valued at $7,133,973 in the last ninety days. Company insiders own 6.70% of the company’s stock.
Supernus Pharmaceuticals Company Profile
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.